VISION & MISSION
We are committed to making lives better with medicines that precisely edit RNA.
Our vision: To harness advances in genetics to develop medicines that improve human health.
Our mission: To be the leading RNA editing company delivering precision therapies to patients with rare and common diseases.
At AIRNA, we are developing potent RNA editing therapeutics to offer more hope to patients who currently have limited options. The passion, dedication, and wealth of knowledge of our team, combined with the data we have generated, makes me very confident in our approach.
Victor De Jesus
Associate Scientist
As someone whose life was transformed by medical breakthroughs, it’s a privilege to be part of a company that is pioneering RNA editing to serve patients with unmet need.
Sruthi V. Hindupur
Senior Scientist
Rodger Novak, MD
Board Chair
Arch Venture Partners
Forbion
Venrock
RTW
Nextech
ND Capital
Robert Altshuler, PhD
Director, Bioinformatics
Namita Bisaria, PhD
Head of Research Strategy and Operations
Peter Borsos
Research Associate
Elisangela Bressan, PhD
Senior Scientist
Josh Brumm
Forbion
Maegan Brunelle
Accounting Manager
Martina Buttschardt
Research Associate
Li-Hao Chang
Scientist
Aindrila Chatterjee, PhD
Senior Scientist
Charles Conover, PhD
Vice President, Program Management
Victor De Jesus
Associate Scientist
Eva-Maria Duerr, PhD
Senior Scientist
Jacob S. Elkins, MD
Chief Medical Officer
Kris Elverum
President and Chief Executive Officer
Kris Elverum
President and Chief Executive Officer, AIRNA
Juri Eyberg, PhD
Senior Scientist
Kat Feldmann
Senior Executive Assistant
Lena Fischer
Vice President, Finance & Operations
Patrick Foster, PhD
Vice President and Head of CMC
Ina Gerber
Associate Director, HR & Finance
Veronica Giachin
Research Associate
Hyun Gyung Jang, PhD
Director DMPK & Clinical Pharmacology
Matthew Hawryluk, PhD
Chief Business Officer
Sruthi V. Hindupur, PhD
Senior Scientist
Inga Jarmoskaite, PhD
Senior Scientist
Sean Kendall, MS
ARCH Venture Partners
Robin Klimek, PhD
Senior Scientist
Kaiko Kunii
In Vivo Pharmacologist
Jin Billy Li, PhD
Stanford University
Konstantin Licht, PhD
Senior Scientist
Dirk Lindenblatt, PhD
Senior Scientist
Aline Mack
Research Associate
Kristyn McCandless
Associate Director, Legal
Amy Mendel
Interim Chief Legal Officer
Tobias Merkle, PhD
Vice President, Platform
Daniella Mizurini, PhD
Associate Principal Scientist
Melissa McCracken, PhD
Nextech
Negin Namazian
Senior Research Associate
Angelika Oswald, PhD
Scientist
Aakash Parikh
Lab Manager
Elena Poser, PhD
Principal Scientist
Piotr Putaj, PhD
Associate Director, Chemistry
Fernanda Sachenbacher, PhD
Senior Scientist
Lange Yakubu Saleh, PhD
Scientist
Sriram Sathy, PhD
Chief Scientific Officer
Carolin Schlitz
Research Associate
Anindya Sen, PhD
Vice President, Preclinical Development
Devyn Smith, PhD
Arbor Bio
Luise Stafforst, PhD
Lab manager
Thorsten Stafforst, PhD
University of Tübingen
Thorsten Stafforst, PhD
University of Tübingen
Stephen Su, PhD
Senior Director, Target Validation
Rewati Tappu, PhD
Senior Scientist
Colleen Tucker, MS
Head of People
Manvi Upadhyay
Senior Research Associate
Paul Vogel, PhD
Vice President, Discovery
Paul Vogel, PhD
Vice President, Discovery
Christopher Volkert
Senior Research Associate